Skip to main content
Erschienen in: Digestive Diseases and Sciences 5/2010

01.05.2010 | Original Article

Increased Prevalence of Reduced Estimated Glomerular Filtration Rate in Chronic Hepatitis C Patients

verfasst von: Sorin A. Petre, Mankanwal S. Sachdev, Brie N. Noble, Marianne Rosati, Marek J. Mazur, Raymond L. Heilman, M. Edwyn Harrison, David D. Douglas, Vijayan Balan

Erschienen in: Digestive Diseases and Sciences | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

To investigate the prevalence and severity of reduced estimated glomerular filtration rate (eGFR) in patients with chronic hepatitis C (CHC).

Methods

Medical record review of 831 consecutive CHC patients seen in our clinic between July 2000 and August 2003; eGFR was estimated using the abbreviated Modification of Diet in Renal Disease (aMDRD) equation. The stage of kidney disease was determined based on eGFR expressed in milliliters per minute per 1.73 m2: stage 1 (signs of kidney damage but normal or elevated (eGFR ≥ 90), stage 2 (eGFR 60–89), stage 3 (30–59), stage 4 (eGFR 15–29), stage 5 (eGFR < 15 or dialysis-dependent).

Results

A total of 522 patients had available data with using the aMDRD equation, 51% had abnormal eGFR (stage 1, 4.6%; stage 2, 36.4%; stage 3 or 4, 6.1%; stage 5, 3.8%). Of 190 patients with stage 2 kidney disease, 189 patients (99.5%) had normal serum creatinine and only one patient (0.5%) had elevated creatinine concentrations (>1.4 mg/dl). Of the 32 patients with stage 3 or 4 disease, 20 (62.5%) had a normal serum creatinine concentration. Of 349 patients without diseases known to cause renal insufficiency, 38% had stage 2–4 renal disease. In a subset of these patients, 95/522 (18%) the measured creatinine clearance showed good correlation with their aMDRD (R = 0.47, (p < 0.0001).

Conclusions

In CHC patients, a normal serum creatinine concentration does not assure normal kidney function. Estimation of eGFR with the aMDRD equation is a more accurate method of identifying patients with chronic kidney disease and reduced eGFR. Therefore, CHC patients should be screened more rigorously for chronic kidney disease because of the high prevalence of reduced eGFR. Lastly, in all CHC patients, the aMDRD eGFR should be used in each encounter with these patients when assessing their renal function irrespective of their serum creatinine.
Literatur
1.
Zurück zum Zitat Diego JM, Roth D. Treatment of hepatitis C infection in patients with renal disease. Current Opin Nephrol Hypertens. 1998;7:557–562.CrossRef Diego JM, Roth D. Treatment of hepatitis C infection in patients with renal disease. Current Opin Nephrol Hypertens. 1998;7:557–562.CrossRef
2.
Zurück zum Zitat Fabrizi F, Marcelli D, Bacchini G, et al. Antibodies to hepatitis C virus (HCV) in chronic renal failure (CRF) patients on conservative therapy: prevalence, risk factors and relationship to liver disease. Nephrol Dial Transplant. 1994;9:780–784.PubMed Fabrizi F, Marcelli D, Bacchini G, et al. Antibodies to hepatitis C virus (HCV) in chronic renal failure (CRF) patients on conservative therapy: prevalence, risk factors and relationship to liver disease. Nephrol Dial Transplant. 1994;9:780–784.PubMed
3.
Zurück zum Zitat Pol S. Treatment of hepatitis C virus infection in dialysis patients. Nephrol Dial Transplant. 2000;15(Suppl 8):46–48.CrossRefPubMed Pol S. Treatment of hepatitis C virus infection in dialysis patients. Nephrol Dial Transplant. 2000;15(Suppl 8):46–48.CrossRefPubMed
4.
Zurück zum Zitat Pol S, Vallet-Pichard A, Fontaine H, Lebray P. HCV infection and hemodialysis. Semin Nephrol. 2002;22:331–339.PubMed Pol S, Vallet-Pichard A, Fontaine H, Lebray P. HCV infection and hemodialysis. Semin Nephrol. 2002;22:331–339.PubMed
5.
Zurück zum Zitat Saab S, Brezina M, Gitnick G, Martin P, Yee HF Jr. Hepatitis C screening strategies in hemodialysis patients. Am J Kidney Dis. 2001;38:91–97. [see comment].CrossRefPubMed Saab S, Brezina M, Gitnick G, Martin P, Yee HF Jr. Hepatitis C screening strategies in hemodialysis patients. Am J Kidney Dis. 2001;38:91–97. [see comment].CrossRefPubMed
6.
Zurück zum Zitat Pol S, Thiers V, Carnot F, et al. Efficacy and tolerance of alpha-2b interferon therapy on HCV infection of hemodialyzed patients. Kidney Int. 1995;47:1412–1418.CrossRefPubMed Pol S, Thiers V, Carnot F, et al. Efficacy and tolerance of alpha-2b interferon therapy on HCV infection of hemodialyzed patients. Kidney Int. 1995;47:1412–1418.CrossRefPubMed
7.
Zurück zum Zitat Garcia-Valdecasas J, Bernal C, Garcia F, et al. Epidemiology of hepatitis C virus infection in patients with renal disease. J Am Soc Nephrol. 1994;5:186–192.PubMed Garcia-Valdecasas J, Bernal C, Garcia F, et al. Epidemiology of hepatitis C virus infection in patients with renal disease. J Am Soc Nephrol. 1994;5:186–192.PubMed
8.
Zurück zum Zitat Dalrymple LS, Koepsell T, Sampson J, et al. Hepatitis C virus infection and the prevalence of renal insufficiency. Clin J Am Soc Nephrol. 2007;2:715–721.CrossRefPubMed Dalrymple LS, Koepsell T, Sampson J, et al. Hepatitis C virus infection and the prevalence of renal insufficiency. Clin J Am Soc Nephrol. 2007;2:715–721.CrossRefPubMed
9.
Zurück zum Zitat Moe SM, Pampalone AJ, Ofner S, et al. Association of hepatitis C virus infection with prevalence and development of kidney disease. Am J Kidney Dis. 2008;51:885–892.CrossRefPubMed Moe SM, Pampalone AJ, Ofner S, et al. Association of hepatitis C virus infection with prevalence and development of kidney disease. Am J Kidney Dis. 2008;51:885–892.CrossRefPubMed
10.
Zurück zum Zitat Tsui JI, Vittinghoff E, Shlipak MG, O’Hare AM. Relationship between hepatitis C and chronic kidney disease: results from the third national health and nutrition examination survey. J Am Soc Nephrol. 2006;17:1168–1174.CrossRefPubMed Tsui JI, Vittinghoff E, Shlipak MG, O’Hare AM. Relationship between hepatitis C and chronic kidney disease: results from the third national health and nutrition examination survey. J Am Soc Nephrol. 2006;17:1168–1174.CrossRefPubMed
11.
Zurück zum Zitat Daghestani L, Pomeroy C. Renal manifestations of hepatitis C infection. Am J Med. 1999;106:347–354.CrossRefPubMed Daghestani L, Pomeroy C. Renal manifestations of hepatitis C infection. Am J Med. 1999;106:347–354.CrossRefPubMed
12.
Zurück zum Zitat Morales JM, Campistol JM, Dominguez-Gil B. Hepatitis C virus infection and kidney transplantation. Semin Nephrol. 2002;22:365–374.PubMed Morales JM, Campistol JM, Dominguez-Gil B. Hepatitis C virus infection and kidney transplantation. Semin Nephrol. 2002;22:365–374.PubMed
13.
Zurück zum Zitat Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol. 2000;11:1896–1902.PubMed Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol. 2000;11:1896–1902.PubMed
14.
Zurück zum Zitat Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.CrossRefPubMed Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.CrossRefPubMed
15.
Zurück zum Zitat Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461–470.PubMed Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461–470.PubMed
16.
Zurück zum Zitat National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcomes Quality Initiative. Am J Kidney Dis. 2002;39:S1–S266.CrossRef National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcomes Quality Initiative. Am J Kidney Dis. 2002;39:S1–S266.CrossRef
18.
Zurück zum Zitat Duncan L, Heathcote J, Djurdjev O, Levin A. Screening for renal disease using serum creatinine: who are we missing? Nephrol Dial Transplant. 2001;16:1042–1046.CrossRefPubMed Duncan L, Heathcote J, Djurdjev O, Levin A. Screening for renal disease using serum creatinine: who are we missing? Nephrol Dial Transplant. 2001;16:1042–1046.CrossRefPubMed
19.
Zurück zum Zitat Amarapurkar DN, Dhawan P, Kalro RH. Role of routine estimation of creatinine clearance in patients with liver cirrhosis. Indian J Gastroenterol. 1994;13:79–82.PubMed Amarapurkar DN, Dhawan P, Kalro RH. Role of routine estimation of creatinine clearance in patients with liver cirrhosis. Indian J Gastroenterol. 1994;13:79–82.PubMed
20.
Zurück zum Zitat Hogg RJ, Furth S, Lemley KV, et al. National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics. 2003;111:1416–1421.CrossRefPubMed Hogg RJ, Furth S, Lemley KV, et al. National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics. 2003;111:1416–1421.CrossRefPubMed
21.
Zurück zum Zitat Johnson RJ, Willson R, Yamabe H, et al. Renal manifestations of hepatitis C virus infection. Kidney Int. 1994;46:1255–1263.CrossRefPubMed Johnson RJ, Willson R, Yamabe H, et al. Renal manifestations of hepatitis C virus infection. Kidney Int. 1994;46:1255–1263.CrossRefPubMed
22.
Zurück zum Zitat Sharara AI, Hunt CM, Hamilton JD. Hepatitis C. Ann Intern Med. 1996;125:658–668. [see comment].PubMed Sharara AI, Hunt CM, Hamilton JD. Hepatitis C. Ann Intern Med. 1996;125:658–668. [see comment].PubMed
23.
Zurück zum Zitat Yamabe H, Johnson RJ, Gretch DR, et al. Hepatitis C virus infection and membranoproliferative glomerulonephritis in Japan. J Am Soc Nephrol. 1995;6:220–223.PubMed Yamabe H, Johnson RJ, Gretch DR, et al. Hepatitis C virus infection and membranoproliferative glomerulonephritis in Japan. J Am Soc Nephrol. 1995;6:220–223.PubMed
24.
Zurück zum Zitat Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third national health and nutrition examination survey. Am J Kidney Dis. 2003;41:1–12.CrossRefPubMed Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third national health and nutrition examination survey. Am J Kidney Dis. 2003;41:1–12.CrossRefPubMed
25.
Zurück zum Zitat Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med. 1992;327:1490–1495.PubMedCrossRef Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med. 1992;327:1490–1495.PubMedCrossRef
26.
Zurück zum Zitat Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982. [see comment].CrossRefPubMed Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982. [see comment].CrossRefPubMed
27.
Zurück zum Zitat Maddrey WC. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. Semin Liver Dis. 1999;19(Suppl 1):67–75.PubMed Maddrey WC. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. Semin Liver Dis. 1999;19(Suppl 1):67–75.PubMed
28.
Zurück zum Zitat Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965. [see comment].CrossRefPubMed Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965. [see comment].CrossRefPubMed
29.
Zurück zum Zitat Balan V, Schwartz D, Wu GY, et al. Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin. Am J Gastroenterol. 2005;100:299–307.CrossRefPubMed Balan V, Schwartz D, Wu GY, et al. Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin. Am J Gastroenterol. 2005;100:299–307.CrossRefPubMed
30.
Zurück zum Zitat Okuda K, Hayashi H, Yokozeki K, et al. Interferon treatment for chronic hepatitis C in haemodialysis patients: suggestions based on a small series. J Gastroenterol Hepatol. 1995;10:616–620.CrossRefPubMed Okuda K, Hayashi H, Yokozeki K, et al. Interferon treatment for chronic hepatitis C in haemodialysis patients: suggestions based on a small series. J Gastroenterol Hepatol. 1995;10:616–620.CrossRefPubMed
31.
Zurück zum Zitat Degos F, Pol S, Chaix ML, et al. The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection: a multicentre, prospective study. Nephrol Dial Transplant. 2001;16:1017–1023.CrossRefPubMed Degos F, Pol S, Chaix ML, et al. The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection: a multicentre, prospective study. Nephrol Dial Transplant. 2001;16:1017–1023.CrossRefPubMed
32.
Zurück zum Zitat Koenig P, Vogel W, Umlauft F, et al. Interferon treatment for chronic hepatitis C virus infection in uremic patients. Kidney Int. 1994;45:1507–1509.CrossRefPubMed Koenig P, Vogel W, Umlauft F, et al. Interferon treatment for chronic hepatitis C virus infection in uremic patients. Kidney Int. 1994;45:1507–1509.CrossRefPubMed
33.
Zurück zum Zitat Chan TM, Wu PC, Lau JY, et al. Interferon treatment for hepatitis C virus infection in patients on haemodialysis. Nephrol Dial Transplant. 1997;12:1414–1419.CrossRefPubMed Chan TM, Wu PC, Lau JY, et al. Interferon treatment for hepatitis C virus infection in patients on haemodialysis. Nephrol Dial Transplant. 1997;12:1414–1419.CrossRefPubMed
Metadaten
Titel
Increased Prevalence of Reduced Estimated Glomerular Filtration Rate in Chronic Hepatitis C Patients
verfasst von
Sorin A. Petre
Mankanwal S. Sachdev
Brie N. Noble
Marianne Rosati
Marek J. Mazur
Raymond L. Heilman
M. Edwyn Harrison
David D. Douglas
Vijayan Balan
Publikationsdatum
01.05.2010
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 5/2010
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-010-1170-0

Weitere Artikel der Ausgabe 5/2010

Digestive Diseases and Sciences 5/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.